• Xcell Therapeutics faces potential KOSDAQ “management stock” designation if its common-share market cap stays below KRW 20 billion.
• The market cap had remained under the threshold for 25 consecutive trading days as of Oct. 12, 2026.
• Designation risk triggers if the sub-KRW 20 billion market cap persists for five more trading days from Oct. 13, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xcell Therapeutics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261012900605), on October 12, 2026, and is solely responsible for the information contained therein.